| Literature DB >> 30238143 |
Tian-Qiong Shi1, He Huang2,3,4, Eduard J Kerkhoven5, Xiao-Jun Ji6,7,8.
Abstract
The oleaginous yeast Yarrowia lipolytica is widely used for the production of both bulk and fine chemicals, including organic acids, fatty acid-derived biofuels and chemicals, polyunsaturated fatty acids, single-cell proteins, terpenoids, and other valuable products. Consequently, it is becoming increasingly popular for metabolic engineering applications. Multiple gene manipulation tools including URA blast, Cre/LoxP, and transcription activator-like effector nucleases (TALENs) have been developed for metabolic engineering in Y. lipolytica. However, the low efficiency and time-consuming procedures involved in these methods hamper further research. The emergence of the CRISPR/Cas system offers a potential solution for these problems due to its high efficiency, ease of operation, and time savings, which can significantly accelerate the genomic engineering of Y. lipolytica. In this review, we summarize the research progress on the development of CRISPR/Cas systems for Y. lipolytica, including Cas9 proteins and sgRNA expression strategies, as well as gene knock-out/knock-in and repression/activation applications. Finally, the most promising and tantalizing future prospects in this area are highlighted.Entities:
Keywords: CRISPR/Cas; Genome editing; Metabolic engineering; Yarrowia lipolytica
Mesh:
Substances:
Year: 2018 PMID: 30238143 PMCID: PMC6208947 DOI: 10.1007/s00253-018-9366-x
Source DB: PubMed Journal: Appl Microbiol Biotechnol ISSN: 0175-7598 Impact factor: 4.813
Fig. 1The CRISPR/Cas genome editing platform for Yarrowia lipolytica. a CRISPR/Cas9 method for gene knock-out/knock-in. When the sgRNA recognizes the targeted sequence, which is located before a protospacer adjacent motif (PAM) site, the Cas9 protein will catalyze the formation of a double-strand break (DSB) in the targeted DNA. In order to repair the genome, two kinds of repair mechanisms can be used. The non-homologous end-joining (NHEJ) repair mechanism, which is dominant in Y. lipolytica, can quickly repair the genome at the expense of the deletion or insertion of a few nucleotides, which can lead to the frameshift mutations in the targeted gene. Additionally, in the presence of a homologous sequence, cells can use the donor DNA to introduce nested heterologous genes or disrupt a targeted gene by homologous recombination (HR), homology-mediated end-joining (HMEJ), and microhomology-mediated end-joining (MMEJ) repair mechanisms. b CRISPRi and CRISPRa methods for gene interference and activation, respectively. A catalytically deactivated Cas9 (dCas9), which has no cleavage activity, can be fused with different effector domains to control gene expression. When the targeted region is recognized, the dCas9 fusion protein with the transcriptional repressor domain binds the DNA to repress gene expression. Similarly, the fusion protein of dCas9 and a transcriptional activator domain binds to targeted regions to improve the gene expression level
Recent applications of the CRISPR/Cas system in Yarrowia lipolytica
| sgRNA expression strategy | Cas9/dCas9 expression strategy | Application | Editing efficiency | References |
|---|---|---|---|---|
| SCR1-tRNAGly ; HH-HDV | Plasmid-based | Knockout studies of XDH and XKS | – | Rodriguez et al. |
| SCR1-tRNAGly | Plasmid-based | CRISPR/Cas9 tool for targeted, markerless gene integration | ~ 50% | Schwartz et al. |
| SCR1-tRNAGly | Plasmid-based | Disrupting TRP1 | – | Wagner et al. |
| SCR1-tRNAGly ; dual sgRNA cleavage | Plasmid-based | A dual-cleavage strategy for gene integration | 14.3–32.6% | Gao et al. |
| tRNA promoter; Biobrick assembly; multiplex sgRNA target | Genomic integration | CRISPR/Cas9 tool for marker-free gene integration | 90% | Holkenbrink et al. |
| HH-HDV; multiplex sgRNA target | Plasmid-based | CRISPR/Cas9 tool for gene knockout | 28–98% | Gao et al. |
| SCR1-tRNAGly | Plasmid-based | Disrupting TRP1 | – | Markham et al. |
| SCR1-tRNAGly | Plasmid-based | CRISPR/Cas9 tool | ~ 90% | Schwartz et al. |
| SCR1-tRNAGly | Plasmid-based | Knocking out glycogen synthesis | – | Bhutada et al. |
| T7 promoter | Plasmid-based | Knocking out the CAN1 gene | 60% | Morse et al. |
| SCR1-tRNAGly ; multiplex sgRNA target | Plasmid-based | Enhancing HR | 90% | Schwartz et al. |
| SCR1-tRNAGly ; Golden-Brick assembly; multiplex sgRNA target | Plasmid-based dCas9 and dCas9-KRAB | CRISPRi tool for gene repression | 92% | Zhang et al. |
| SCR1-tRNAGly ; multiplex sgRNA target | Plasmid-based dCas9-VPR fusion protein | CRISPRa system for activation of cryptic sugar metabolism | – | Schwartz and Wheeldon |
| HH-HDV | Plasmid-based | YaliBricks-based CRISPR/Cas9 tool | 12.5% | Wong et al. |
–, not stated